Efficacy and Tolerability of Exenatide Once Weekly over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study

Diabetes Technology and Therapeutics

Volumn 18, Issue 11, 2016, Pages 677-686

  Henry, Robert R ^a   Klein, Eric J ^b   Han, Jenny ^c   Iqbal, Nayyar ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Capital Medical Center   (United States)

^c Pharmapace Inc   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BROMOCRIPTINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ADULT; ARTHRALGIA; ARTICLE; BODY WEIGHT; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INJECTION SITE PRURITUS; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 84997124377     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2016.0107     Document Type: Article

References (17)

1. U.K. Prospective Diabetes Study Group: U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-1258.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patientcentered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38: 140-149.
3. Buse JB, Drucker DJ, Taylor KL, et al.: DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33: 1255-1261.
4. Taylor K, Gurney K, Han J, et al.: Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord 2011; 11:9.
5. MacConell L, Pencek R, Li Y, et al.: Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes 2013;6:31-41.
6. Wysham CH, MacConell LA, Maggs DG, et al.: Five-year efficacy and safety data of exenatide once weekly: longterm results from the DURATION-1 randomized clinical trial. Mayo Clin Proc 2015;90:356-365.
7. Drucker DJ, Buse JB, Taylor K, et al.: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
8. World Medical Association: World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925-926.
9. Garber A, Henry RR, Ratner R, et al.: Liraglutide, a oncedaily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011;13:348-356.
10. Ahren B, Johnson SL, Stewart M, et al.: HARMONY 3: 104-week randomized, double-blind, placebo- and activecontrolled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014;37:2141-2148.
11. Klonoff DC, Buse JB, Nielsen LL, et al.: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286.
12. DiamantM, VanGaal L, Guerci B, et al.: Exenatide onceweekly versus insulin glargine for type 2 diabetes (DURATION-3): 3- year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014;2:464-473.
13. Trautmann M, Van Gaal L, Han J, et al.: Three-year efficacy and safety of exenatide once weekly: a pooled analysis of 3 trials. Diabetes 2015;64(Suppl. 1):A287.
14. MacConell L, Brown C, Gurney K, et al.: Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012;5:29-41.
15. MacConell L, Gurney K, Malloy J, et al.: Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4, 328 patients. Diabetes Metab Syndr Obes 2015;8:241-253.
16. Sun F, Wu S, Guo S, et al.: Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract 2015;110:26-37.
17. Starner CI, Schafer JA, Heaton AH, et al.: Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008;14:523-531.